Show Summary Details
Page of

Neuroendocrine tumours 

Neuroendocrine tumours
Neuroendocrine tumours

Jamshed Bomanji

and G. Gnanasegaran

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 23 October 2020

Chapter 5 discusses general principles of radionuclide therapy with regard to neuroendocrine tumours (NETs), which are rare, slow-growing malignancies and have distinct biological and clinical characteristics, and includes 131I-Meta-iodobenzylguanidine (131I-mIBG) therapy, peptides, recent advances and future concern, radioembolization/intra-arterial 90Y-Lanreotide therapy, medical management, hepatic artery chemoembolization, and radiotherapy for neuroendocrine tumours.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.